Oligometastases Treated With Stereotactic Body Radiotherapy: Long-Term Follow-Up of Prospective Study

Milano, Michael T.; Katz, Alan W.; Zhang, Hong; Okunieff, Paul

doi:10.1016/j.ijrobp.2011.08.036

Cited by 389 publications

(274 citation statements)

References 53 publications

Supporting

Mentioning

248

Contrasting

Unclassified

Order By: Relevance

“…Milano et al performed a prospective study of 121 patients with five or fewer metastatic lesions, metastatic to one to three organ sites, treated with SABR. Multiple sites were treated including lung, liver, brain and bone [15]. The preferred treatment schedule was 50 Gy in 10 fractions.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Stereotactic Ablative Body Radiotherapy for the Treatment of Spinal Oligometastases

et al. 2017

View full text Add to dashboard Cite

After the embargo period via non-commercial hosting platforms such as their institutional repository  via commercial sites with which Elsevier has an agreement In all cases accepted manuscripts should: link to the formal publication via its DOI  bear a CC-BY-NC-ND license -this is easy to do, click here to find out how  if aggregated with other manuscripts, for example in a repository or other site, be shared in alignment with our hosting policy  not be added to or enhanced in any way to appear more like, or to substitute for, the published journal article This cohort warrants further investigation in clinical trials of SABR.

show abstract

Section: Discussionmentioning

confidence: 99%

“…WFFS was defined as the time from completion of SABR until widespread failure or death. We chose this as the primary endpoint to allow comparison to a previous study of SABR for oligometastases, which used a similar primary endpoint [15].…”

Section: Introductionmentioning

confidence: 99%

Stereotactic Ablative Body Radiotherapy for the Treatment of Spinal Oligometastases

et al. 2017

View full text Add to dashboard Cite

show abstract

“…12 For liver metastases from OM BC, in different series, the 2-year local control rates varies between 57 and 92%, and radiation-induced liver damage is exceptional. [12][13][14] Based on these encouraging data, SBRT for liver lesions in OM BC represents a valid alternative local therapy in patients unsuitable for surgery.…”

Section: State Of the Artmentioning

confidence: 97%

“…14 The authors enrolled 121 patients with five or fewer clinically detectable metastases, from any primary site, metastatic to one to three organ sites, and treated with SBRT. Limiting the analysis to breast cancer patients (39), the 2-year OS, freedom from widespread distant metastases (FFDM), and local control (LC) rate were 74%, 52%, and 87%, respectively.…”

Section: Current Literature Datamentioning

confidence: 99%

The role of SBRT in oligometastatic patients with liver metastases from breast cancer

Scorsetti

Franceschini

Rose

et al. 2017

Reports of Practical Oncology & Radiotherapy

View full text Add to dashboard Cite

Liver Metastases SBRT Radiotherapy a b s t r a c tLiver metastases from breast cancer are a common occurrence. Local ablative therapies are a promising therapeutic option for these patients, with the potential for a long term disease control in the setting of "oligometastatic patients". Identification of the perfect candidate for local approaches is still challenging and unclear. Stereotactic body radiation therapy (SBRT) is one of the most valuable local therapy, because of great efficiency, low morbidity and minimal invasiveness. In this paper, we reviewed the state of the art in the care of breast cancer patients with liver metastases, with a focus on SBRT.© 2016 Greater Poland Cancer Centre. Published by Elsevier Sp. z o.o. All rights reserved. 1.State of the art E-mail address: marta.scorsetti@humanitas.it (M. Scorsetti).Firstly in 1995, Hellman and Weichselbaum 1 described the state, called oligometastatic disease, characterized by an indolent tumor biology and behavior in which metastases are limited in number and site. In this subgroup of selected patients, the emerging data is that local therapy could have a potential curative role and an impact on survival rate.The population with oligometastatic BC (OM BC) is estimated to be 1-10% of newly diagnosed patients with metastatic BC 2 and is well represented in the subgroup of http://dx

show abstract

“…Patients with long latency periods after treatment to the primary tumor are thought to have an improved prognosis compared to patients with synchronous metastatic disease (5,8). Milano et al reported that in patients with metastatic breast cancer, those with progression after systemic therapy who then were treated with SBRT to limited metastases had a 2-year OS rate of 15%, compared to 55% in those who had stable or regressing disease after primary treatment, again indicating that proper clinically based selection of patients for treatment may be as important as the type of treatment offered (16). With rapid advances in genomic and molecular assays, investigators are now working to identify oligometastatic signatures that could be used clinically to guide management decisions.…”

mentioning

confidence: 99%

Is there a benefit to locally consolidative therapy for oligometastatic non-small cell lung cancer?

Boreta

Yom

2017

Ann. Transl. Med.

View full text Add to dashboard Cite

show abstract

Oligometastases Treated With Stereotactic Body Radiotherapy: Long-Term Follow-Up of Prospective Study

Cited by 389 publications

References 53 publications

Stereotactic Ablative Body Radiotherapy for the Treatment of Spinal Oligometastases

Stereotactic Ablative Body Radiotherapy for the Treatment of Spinal Oligometastases

The role of SBRT in oligometastatic patients with liver metastases from breast cancer

Is there a benefit to locally consolidative therapy for oligometastatic non-small cell lung cancer?

Contact Info

Product

Resources

About